// App-Quantinova.ai

Abstract 9392 : Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

Researchers

Presenter

  • Mark Petrie

Principal Investigators

  • Stephen Bain

  • Soren Tetens Hoff

  • Nicklas Johansen

  • Sren Rasmussen

  • Tina Vilsboell

  • Mansoor Husain

Medical Centers

  • Swansea Univ Med Sch, Swansea, United Kingdom

  • Ted Rogers Cntr for Heart Rsch, Toronto, Canada

  • Steno Diabetes Cntr Copenhagen, Gentofte Hosp, Univ of Copenhagen, Hellerup, Denmark

  • University of Glasgow, Glasgow, United Kingdom

  • Novo NordiskA/S, Soborg, Denmark

Locations

  • United Kingdom

  • Canada

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Semaglutide

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved